Anaplastic lymphoma kinase in human cancer

Antonella Barreca, Elena Lasorsa, Ludovica Riera, Rodolfo Machiorlatti, Roberto Piva, Maurilio Ponzoni, Ivo Kwee, Francesco Bertoni, Pier Paolo Piccaluga, Stefano A. Pileri, Giorgio Inghirami

Research output: Contribution to journalArticle

Abstract

The receptor tyrosine kinases (RTKs) play a critical role, controlling cell proliferation, survival, and differentiation of normal cells. Their pivotal function has been firmly established in the pathogenesis of many cancers as well. The anaplastic lymphoma kinase (ALK), a transmembrane RTK, originally identified in the nucleophosmin (NPM)-ALK chimera of anaplastic large cell lymphoma, has emerged as a novel tumorigenic player in several human cancers. In this review, we describe the expression of the ALK-RTK, its related fusion proteins, and their molecular mechanisms of activation. Novel tailored strategies are briefly illustrated for the treatment of ALK-positive neoplasms.

Original languageEnglish
JournalJournal of Molecular Endocrinology
Volume47
Issue number1
DOIs
Publication statusPublished - Aug 2011

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology

Fingerprint Dive into the research topics of 'Anaplastic lymphoma kinase in human cancer'. Together they form a unique fingerprint.

  • Cite this

    Barreca, A., Lasorsa, E., Riera, L., Machiorlatti, R., Piva, R., Ponzoni, M., Kwee, I., Bertoni, F., Piccaluga, P. P., Pileri, S. A., & Inghirami, G. (2011). Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology, 47(1). https://doi.org/10.1530/JME-11-0004